Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy

News provided by

Sep 10, 2010, 07:30 ET

BOSTON, Sept. 10 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced the Company's lead product, PTK 0796, a first-in-class aminomethylcycline, will be the subject of several poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Dr. Stuart Levy, co-founder and Chief Scientific Officer of Paratek will also be delivering a talk at a symposium on antibiotic resistance at the conference. ICAAC will be held in Boston, Massachusetts from September 12 - September 15, 2010.

More information on the poster sessions and symposium at ICAAC:


Sunday, September 12, 11:30 a.m.– 1:30 p.m. EDT
Session 002; Pharmacology of Oxazolidinones and Miscellaneous Antibacterial Agents Location: Exhibit Hall B1 Poster: A1-022, Board#19
Pharmacokinetics of Intravenous and Oral PTK796, A New Aminomethylcycline Antibiotic.
Sunday, September 12, 11:30 a.m.– 1:30 p.m. EDT
Session 004; Antibiotic Therapy of Vascular Infections in Animal Models Location: Exhibit Hall B1 Poster: B-069, Board#70
Efficacy of PTK796 in a Rat MRSA Infected Endocarditis (IE) Model.
Sunday, September 12, 4:00 p.m.– 4:50 p.m. EDT
Session 032; How 50 Years of Antibacterial Drug Development has Been Driven by Antibiotic Resistance Location: Room 052A Presentation: 456 Presenter: Stuart B. Levy, M.D.
A Tetracycline Renaissance.
Tuesday, September 14, 11:15 a.m.- 1:15 p.m. EDT
Session 169; Antibiotic Resistance in Gram-Negative Bacteria Other than Enterobacteriacea Location: Exhibit Hall B1 Poster: C1-1413, Board#68
Studies on the Mechanism of Resistance to PTK796 in Pseudomonas aeruginosa and Klebsiella pneumoniae.
Tuesday, September 14, 11:15 a.m.– 1:15 p.m. EDT
Session 176; Anti-Staphylococcal Agents: In Vitro/In Vivo Efficacy Location: Exhibit Hall B1 Poster: E-1569, Board#232
In Vitro Evaluation of PTK 0796 Activity Tested against Staphylococcus aureus, Including Hospital- and Community-Associated MRSA Strains from the USA and Europe.
Tuesday, September 14, 11:15 a.m.– 1:15 p.m. EDT
Session 177; In Vitro Efficacy of Antimicrobials against Gram-Positive Bacteria Location: Exhibit Hall B1 Poster: E-1588, Board#254
Antimicrobial Activity of PTK 0796 Tested against Gram-Positive Organisms Causing Bloodstream Infections in 2009.
Tuesday, September 14, 11:15 a.m.– 1:15 p.m. EDT
Session 191; Treatment Issues in Gram-Positive Infections Location: Exhibit Hall B1 Poster: L1-1760, Board#445
Identification and Susceptibility of Pathogens Isolated from Patients with Complicated Skin and Skin Structure Infections (cSSSI): Results of a PTK 0796 (PTK) Phase 2 Clinical Trial.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases, with a particular focus on the growing worldwide problem of antibiotic resistance. Paratek is advancing novel compounds that can circumvent or block bacterial resistance. Paratek's lead compound, PTK 0796, is a broad-spectrum antibiotic derived from the tetracycline class with oral and IV formulations that is being developed for the treatment of the most common and serious hospital bacterial infections, including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae). Oral and IV formulations of PTK 0796 were compared to Zyvox ® in a Phase 2 clinical study in complicated skin and skin structure infections (cSSSI). In addition to PTK 0796, Paratek is also developing other tetracycline antibiotics to treat hospital and community infections based on its novel tetracycline chemistry expertise.

Based upon a growing body of clinical research and as part of its effort to exploit its novel tetracycline derivatives and their unique mechanism of action in selected inflammatory and neurodegenerative conditions, Paratek has an active chemical synthesis effort to produce novel and diverse small molecules, with the goal of developing nonantibacterial tetracycline derivatives with improved activity in serious inflammatory and neurodegenerative diseases. In addition, Paratek is encouraged by early evidence of the ability of tetracycline derivatives to affect mRNA splicing, as in spinal muscular atrophy (SMA). Outside of its tetracycline antibacterial program, Paratek has also identified small molecules that inhibit bacteria-specific transcription factors for Multiple Adaptational Response (MAR) genes which control bacterial virulence and resistance development.

Paratek has active collaborations with Novartis, Warner-Chilcott and FSMA to develop tetracycline-derived small molecule drugs for a range of uses, including bacterial infections, acne & rosacea and SMA. Paratek is privately held and headquartered in Boston, Massachusetts, USA. For more information about Paratek and its research and development initiatives, visit Paratek's website at http://www.paratekpharm.com.

SOURCE Paratek Pharmaceuticals, Inc.